诊断性131I SPECT/CT在甲状腺微小乳头状癌患者长期随访中的作用
该回顾性研究纳入351例甲状腺切除及放射性碘治疗后的甲状腺微小乳头状癌患者,随访期间行诊断性131I全身扫描(WBS)及SPECT/CT。SPECT/CT较WBS检出并正确分类更多转移灶,减少假阳性,并在38.1%阳性患者中提供增量价值、21.6%患者中改变分类与治疗管理。作者建议将131I SPECT/CT更广泛用于诊断流程。
要点
- 长期随访中8.5%的甲状腺微小乳头状癌患者发生转移。
- SPECT/CT在极低危、WBS结果不明确、T1aN0M0及甲状腺球蛋白检测不到或极低的患者中表现更优。
- SPECT/CT在38.1%阳性患者中具增量价值,在21.6%患者中改变分类与治疗管理。
核心结论
- 长期随访中8.5%的患者发生转移。
- SPECT/CT表现优于WBS,尤其在极低危、WBS结果不明确、TNM分期为T1aN0M0及甲状腺球蛋白检测不到或极低的患者中。
- 甲状腺微小乳头状癌患者有理由延长监测,并建议(弱推荐)在诊断流程中更广泛使用131I SPECT/CT。
研究设计与样本
- 回顾性研究纳入351例连续甲状腺微小乳头状癌患者,均行甲状腺切除术及放射性碘治疗;其中21例高危、94例低危、236例极低危。
- 随访期间患者行诊断性131I全身扫描(WBS),随后行SPECT/CT。
主要发现
- WBS在126例患者中发现248个摄碘灶,SPECT/CT在139例患者中发现298个摄碘灶,并确认了WBS的所有病灶。
- SPECT/CT将76个摄碘灶正确分类为WBS上不明确或错误分类的病灶。
- SPECT/CT在30例转移患者中的27例检出并正确分类64个肿瘤病灶;WBS在30例中的16例显示64个病灶中的39个,其中28个不明确或错误分类。
- 27例转移患者中19例(包括13例极低危)仅有颈部转移,其中9例为T1aN0M0且甲状腺球蛋白检测不到;3例(包括1例极低危)仅有远处转移且甲状腺球蛋白检测不到或极低;5例有颈部及远处转移,甲状腺球蛋白水平1例<2.5 ng/mL、3例在2.5至10之间、剩余1例>10。
- SPECT/CT在139例中的15例(10.8%)减少了WBS假阳性结果;在38.1%的阳性发现患者中具增量价值,在21.6%患者中改变分类与治疗管理。
关键数值与推荐
- 转移发生于8.5%的患者(长期随访期间)。
- SPECT/CT在139例中的15例(10.8%)减少WBS假阳性结果。
- SPECT/CT在38.1%的阳性发现患者中具增量价值,在21.6%患者中改变分类与治疗管理。
临床怎么用
- 作者建议(弱推荐)在甲状腺微小乳头状癌诊断流程中更广泛使用131I SPECT/CT。
- 作者认为甲状腺微小乳头状癌患者有理由延长监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Papillary thyroid microcarcinoma (PTMC) usually has a favorable prognosis but can also be aggressive, with neck and distant metastases. We evaluated the diagnostic role of 131I SPECT/CT in detecting metastases in PTMC patients during long-term follow-up and whether the procedure should be included in the current diagnostic protocol. Methods: We retrospectively studied 351 consecutive PTMC patients who had undergone thyroidectomy and radioiodine therapy; 21 were at high risk, 94 at low risk, and 236 at very low risk. During follow-up, the patients underwent diagnostic 131I whole-body scanning (WBS) followed by SPECT/CT. Results: WBS found 248 radioiodine-avid foci in 126 patients, and SPECT/CT found 298 in 139 patients, confirming all foci found on WBS. SPECT/CT also correctly classified 76 of the avid foci as unclear or wrongly classified on WBS. Globally, SPECT/CT detected and correctly classified 64 neoplastic lesions in 27 of 30 patients with metastases, and WBS evidenced 39 of 64 lesions, 28 of which were unclear or wrongly classified, in 16 of the 30 patients. Nineteen of 27 patients, including 13 at very low risk, had only neck metastases, 9 of 19 being T1aN0M0 with an undetectable thyroglobulin level. Three of 27 patients, including 1 at very low risk, had only distant metastases with an undetectable or very low thyroglobulin level. Five of 27 patients had neck and distant metastases with a thyroglobulin level <2.5 ng/mL in 1 case, between 2.5 and 10 in 3 cases, and >10 in the remaining case. SPECT/CT also reduced WBS false-positive results in 15 of 139 patients (10.8%). SPECT/CT had an incremental value over WBS in 38.1% of patients with positive findings and changed the classification and therapeutic management in 21.6%. Conclusion: Metastases occurred in 8.5% of patients during long-term follow-up. SPECT/CT performed better than WBS, particularly in patients at very low risk with inconclusive WBS results, a TNM stage of T1aN0M0, and an undetectable or very low level of thyroglobulin. Prolonged surveillance is justified in PTMC patients, and wider use of 131I SPECT/CT in the diagnostic protocol is suggested.
引用
- Spanu A, Nuvoli S, Gelo I, et al. Role of Diagnostic 131I SPECT/CT in Long-Term Follow-up of Patients with Papillary Thyroid Microcarcinoma. J Nucl Med. 2018. PMID: 29496990. doi:10.2967/jnumed.117.204636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。